Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin

Journal of Physiology and Pharmacology

Volumn 66, Issue 2, 2015, Pages 159-167

  Han, Y M ^a   Park, J M ^a   Kangwan, N ^a   Jeong, M ^a   Lee, S ^a   Cho, J Y ^b   Ko, W J ^b   Hahm, Ki Baik ^a,b  

^a Cancer Prevention Research Center   (South Korea)

^b CHA Bundang Medical Center   (South Korea)

Author keywords

Anti carcinogenesis; Cancer prevention; Colorectal cancer; Gastrin; Proton pump inhibitors; Trophic action; Warburg effect

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CD24 ANTIGEN; CHOLECYSTOKININ B RECEPTOR; CYCLOOXYGENASE 2; ESOMEPRAZOLE; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GAMMA INTERFERON; GASTRIN; GASTRIN RELEASING PEPTIDE RECEPTOR; HERMES ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; OMEPRAZOLE; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC AGENT; PROTON PUMP;

ACTINOBACTERIA; ANGIOGENESIS; APOPTOSIS; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA ASSOCIATED CARCINOGENESIS; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RISK FACTOR; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; STOMACH NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; GASTRINS; HUMANS; PROTON PUMP INHIBITORS; PROTON PUMPS; STOMACH NEOPLASMS;

EID: 84927522220     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Waldum HL, Brenna E. Role of the enterochromaffin-like cells and histamine in the regulation of gastric acid secretion. Gastroenterol Clin Biol 1991; 15: 65C-72C.
2. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 2001; 63: 49-76.
3. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709-723; discussion, 724-708.
4. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 (Suppl. 1): 42-55.
5. McGuigan JE, Trudeau WL. Serum and tissue gastrin concentrations in patients with carcinoma of the stomach. Gastroenterology 1973; 64: 22-25.
6. Kumamoto T. Gastrin receptors in human gastric scirrhous carcinoma. Gastroenterol Jpn 1988; 23: 384-389.
7. Ueki T, Koji T, Tamiya S, Nakane PK, Tsuneyoshi M. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol 1995; 177: 353-361.
8. Fourmy D, Gigoux V, Reubi JC. Gastrin in gastrointestinal diseases. Gastroenterology 2011; 141: 814-818.
9. Smith JP, Rickabaugh CA, McLaughlin PJ, Zagon IS. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. Am J Physiol 1993; 265: G149-G155.
10. Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 1994; 266: R277-R283.
11. Green JA, Amaro R, Barkin JS. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. Dig Dis Sci 2000; 45: 2367-2368.
12. Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett’s and colorectal carcinogenesis. World J Gastroenterol 2012; 18: 6560-6570.
13. 2 production. Br J Pharmacol 2005; 144: 338-348.
14. Chao C, Hellmich MR. Gastrin, inflammation, and carcinogenesis. Curr Opin Endocrinol Diabetes Obes 2010; 17: 33-39.
15. Uberti B, Dentelli P, Rosso A, Defilippi P, Brizzi MF. Inhibition of beta1 integrin and IL-3Rbeta common subunit interaction hinders tumour angiogenesis. Oncogene 2010; 29: 6581-6590.
16. Werner L, Guzner-Gur H, Dotan I. Involvement of CXCR4/CXCR7/CXCL12 Interactions in inflammatory bowel disease. Theranostics 2013; 3: 40-46.
17. Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 2002; 22: 105-114.
18. Smith JP, Solomon TE. Cholecystokinin (CCK) and pancreatic cancer: the chicken or the egg? Am J Physiol Gastrointest Liver Physiol 2014; 306: G91-G101.
19. Harris JC, Clarke PA, Awan A, Jankowski J, Watson SA. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett’s esophagus. Cancer Res 2004; 64: 1915-1919.
20. Selgrad M, Bornschein J, Kandulski A, et al. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. Int J Cancer 2014; 135: 1127-1131.
21. Maddalo G, Spolverato Y, Rugge M, Farinati F. Gastrin: from pathophysiology to cancer prevention and treatment. Eur J Cancer Prev 2014; 23: 258-263.
22. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659: 15-30.
23. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med 2012; 52: 2013-2037.
24. Sordal O, Waldum H, Nordrum IS, et al. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2013; 18: 397-405.
25. Kato S, Tsukamoto T, Mizoshita T, et al. High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells. Int J Cancer 2006; 119: 1558-1566.
26. Konturek PC, Kania J, Kukharsky V, Ocker S, Hahn EG, Konturek SJ. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosisrelated proteins in gastric epithelial cells. J Physiol Pharmacol 2003; 54: 17-32.
27. Konturek PC, Konturek SJ, Bielanski W, et al. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. J Physiol Pharmacol 1999; 50: 857-873.
28. Naito Y, Ito M, Watanabe T, Suzuki H. Biomarkers in patients with gastric inflammation: a systematic review. Digestion 2005; 72: 164-180.
29. Ibiza S, Alvarez A, Romero W, Barrachina MD, Esplugues JV, Calatayud S. Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM1. Am J Physiol Cell Physiol 2009; 297: C1588-C1595.
30. Singh P, Sarkar S, Kantara C, Maxwell C. Progastrin peptides increase the risk of developing colonic tumors: impact on colonic stem cells. Curr Colorectal Cancer Rep 2012; 8: 277-289.
31. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013; 33 (Suppl. 1): S79-S84.
32. Petronilho F, Danielski LG, Roesler R, Schwartsmann G, Dal-Pizzol F. Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update. Inflamm Allergy Drug Targets 2013; 12: 172-177.
33. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-454.
34. Johnson LR. Control of gastric secretion: no room for histamine? Gastroenterology 1971; 61: 106-118.
35. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H 2 -receptors. Nature 1972; 236: 385-390.
36. Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrinhistamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698-701.
37. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-760.
38. Creutzfeldt W. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Drug Saf 1994; 10: 66-82.
39. Muerkoster S, Isberner A, Arlt A, et al. Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo. Gastroenterology 2005; 129: 952-968.
40. Kim YJ, Lee JS, Hong KS, Kim JH, Hahm KB. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila) 2010; 3: 963-974.
41. Yeo M, Kim DK, Han SU, et al. Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut 2006; 55: 26-33.
42. Kedika RR, Souza RF, Spechler SJ. Potential antiinflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009; 54: 2312-2317.
43. Huang S, Chen M, Ding X, Zhang X, Zou X. Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. Int Immunopharmacol 2013; 17: 585-592.
44. Hernandez A, Serrano-Bueno G, Perez-Castineira JR, Serrano A. Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer. Curr Pharm Des 2012; 18: 1383-1394.
45. De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 2005; 6: 1049-1054.
46. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010; 267: 515-525.
47. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322.
48. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drugenteropathy. World J Gastroenterol 2013; 19: 1861-1876.
49. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748-754.
50. Han YM, Hahm KB, Park JM, Hong SP, Kim EH. Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and gastrinin APCMin/+ intestinal polyposis model. Neoplasia 2014; 16: 73-83.
51. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
52. Kim S, Domon-Dell C, Wang Q, et al. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 2002; 123: 1163-1178.
53. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013; 13: 611-623.
54. Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res 2013; 19: 6766-6776.
55. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
56. Antoniou A, Hebrant A, Dom G, Dumont JE, Maenhaut C. Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property? Cell Cycle 2013; 12: 3743-3748.
57. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012; 44: 2144-2151.
58. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 2011; 10: 1385-1393.
59. Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 2013; 114: 21-34.
60. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondria “fuel” breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle 2012; 11: 4390-4401.
61. Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X. ABCG2/V ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol 2012; 7: 180.
62. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011; 10: 4047-4064.
63. Martinez-Outschoorn UE, Pestell RG, Howell A, et al. Energy transfer in “parasitic” cancer metabolism: mitochondria are the powerhouse and Achilles’ heel of tumor cells. Cell Cycle 2011; 10: 4208-4216.
64. Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 2013; 280: 5052-5064.
65. Vazquez-Martin A, Corominas-Faja B, Cufi S, et al. The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle 2013; 12: 207-218.
66. Han YM, Park JM, Park SH, Hahm KB, Hong SP, Kim EH. Gastrin promotes intestinal polyposis through cholecystokinin-B receptor-mediated proliferative signaling and fostering tumor microenvironment. J Physiol Pharmacol 2013; 64: 429-437.
67. Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-3170.
68. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 2013; 20: 382-395.
69. Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 2013; 65: 1763-1783.
70. Pardo LA, Stuhmer W. The roles of K(+) channels in cancer. Nat Rev Cancer 2014; 14: 39-48.